|
WO2001014557A1
(en)
*
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
CA2383424C
(en)
*
|
1999-08-23 |
2011-02-15 |
Gordon Freeman |
Novel b7-4 molecules and uses therefor
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
WO2006042237A2
(en)
|
2004-10-06 |
2006-04-20 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
|
CN104436190A
(zh)
|
2005-06-08 |
2015-03-25 |
达纳-法伯癌症研究院公司 |
通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
|
|
NZ568015A
(en)
|
2005-12-08 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to O8E
|
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
WO2007082154A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
BRPI0715829A2
(pt)
*
|
2006-08-21 |
2013-07-23 |
Hoffmann La Roche |
terapia de tumor com um anticorpo anti-vegf
|
|
JP5601836B2
(ja)
*
|
2006-11-08 |
2014-10-08 |
マクロジェニックス ウエスト， インコーポレイテッド |
Ｔｅｓ７およびｔｅｓ７に結合する抗体
|
|
CA2673870A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
AU2013200388B2
(en)
*
|
2006-12-27 |
2014-10-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for the treatment of infections and tumors
|
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
|
AU2014268176B2
(en)
*
|
2006-12-27 |
2016-03-31 |
Dana-Farber Cancer Institute, Inc |
Compositions and methods for the treatment of infections and tumors
|
|
CA2673752A1
(en)
*
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for stimulating an immune response
|
|
EP2152890A1
(en)
*
|
2007-05-23 |
2010-02-17 |
MannKind Corporation |
Multicistronic vectors and methods for their design
|
|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
CN101784564B
(zh)
|
2007-07-13 |
2014-07-02 |
约翰霍普金斯大学 |
B7-dc变体
|
|
US8062852B2
(en)
*
|
2007-10-01 |
2011-11-22 |
The Children's Hospital And Regional Medical Center |
Detection and treatment of autoimmune disorders
|
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
|
EP2262837A4
(en)
*
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
EP2317992A2
(en)
|
2008-07-24 |
2011-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
EP2328920A2
(en)
*
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
AU2009290543B2
(en)
|
2008-09-12 |
2015-09-03 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
BRPI0920749A8
(pt)
|
2008-10-02 |
2017-12-12 |
Emergent Product Dev Seattle |
Proteínas de ligação de antagonista multialvo cd86
|
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
ES2796111T3
(es)
*
|
2008-11-14 |
2020-11-25 |
Brigham & Womens Hospital Inc |
Métodos terapéuticos relacionados con células madre cancerosas
|
|
EP2370593B1
(en)
|
2008-11-28 |
2016-03-30 |
Emory University |
Methods for determining the efficacy of pd-1 antagonists
|
|
HUE065752T2
(hu)
*
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
US9181525B2
(en)
|
2009-03-06 |
2015-11-10 |
Mie University |
Method for enhancing a function of a T cell
|
|
EP2408818A1
(en)
*
|
2009-03-17 |
2012-01-25 |
Université de la Méditerranée |
Btla antibodies and uses thereof
|
|
US8975247B2
(en)
|
2009-03-18 |
2015-03-10 |
The Board Of Trustees Of The Leland Stanford Junion University |
Methods and compositions of treating a flaviviridae family viral infection
|
|
CA2772204A1
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
WO2011097345A1
(en)
*
|
2010-02-04 |
2011-08-11 |
Virostatics Srl |
Ki-67 assay for patient immune system status
|
|
US20130202623A1
(en)
*
|
2010-02-16 |
2013-08-08 |
Nicolas Chomont |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
EP2552947A4
(en)
|
2010-03-26 |
2013-11-13 |
Dartmouth College |
VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
*
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
CA2842368A1
(en)
*
|
2011-07-29 |
2013-02-07 |
The Trustees Of The University Of Pennsylvania |
Switch costimulatory receptors
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
EP2760471B9
(en)
|
2011-09-30 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
MY171759A
(en)
|
2011-12-06 |
2019-10-28 |
Univ Leland Stanford Junior |
Methods and compositions for treating viral diseases
|
|
WO2013090552A1
(en)
*
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
AU2013221187B9
(en)
|
2012-02-16 |
2018-01-04 |
Vlp Therapeutics, Inc. |
Virus like particle composition
|
|
WO2013155493A1
(en)
|
2012-04-12 |
2013-10-17 |
Yale University |
Methods of treating inflammatory and autoimmune diseases and disorders
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
WO2013177102A2
(en)
*
|
2012-05-21 |
2013-11-28 |
Felder Mitchell S |
Treatment of cancer by manipulating the immune system
|
|
TWI705073B
(zh)
|
2012-06-22 |
2020-09-21 |
達特茅斯學院基金會 |
新穎之vista-ig構築體及vista-ig用於治療自體免疫、過敏及發炎病症之用途
|
|
US9890215B2
(en)
*
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104936982B
(zh)
*
|
2012-08-03 |
2020-04-24 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
JP6368308B2
(ja)
|
2012-09-07 |
2018-08-01 |
トラスティーズ・オブ・ダートマス・カレッジ |
癌の診断および治療のためのｖｉｓｔａ調節剤
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
|
US20150377891A1
(en)
|
2013-02-07 |
2015-12-31 |
(Institute National De La Santé Et De La Rechere Médicale) |
Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas
|
|
CN105073135A
(zh)
|
2013-02-22 |
2015-11-18 |
库瑞瓦格有限责任公司 |
疫苗接种和抑制pd-1途径的组合
|
|
EP3578200A1
(en)
|
2013-02-22 |
2019-12-11 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CA2907249A1
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
KR20250091304A
(ko)
|
2013-03-15 |
2025-06-20 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
KR102243062B1
(ko)
|
2013-05-02 |
2021-04-21 |
아납티스바이오, 아이엔씨. |
예정된 사멸-1에 대한 항체
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
TWI676636B
(zh)
*
|
2013-07-12 |
2019-11-11 |
Ｖｌｐ醫療股份有限公司 |
包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
|
|
WO2015038538A1
(en)
*
|
2013-09-10 |
2015-03-19 |
Medimmune, Llc |
Compositions and methods for treating sepsis
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
EP3052131B1
(en)
|
2013-10-01 |
2018-12-05 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
JP6845691B2
(ja)
|
2013-11-01 |
2021-03-24 |
イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ |
免疫療法のための調節粒子
|
|
BR112016012358A2
(pt)
*
|
2013-12-06 |
2017-09-26 |
Dana Farber Cancer Inst Inc |
peptídios terapêuticos
|
|
ES2746805T3
(es)
|
2013-12-12 |
2020-03-06 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
|
|
RS63295B1
(sr)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Anti-vista antitela i fragmenti
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
WO2015139020A2
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
JP6894236B2
(ja)
*
|
2014-03-26 |
2021-06-30 |
デノボ バイオファーマ エルエルシー |
免疫刺激活性を有するレトロウイルスベクター
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
HUE048677T2
(hu)
|
2014-06-19 |
2020-07-28 |
Regeneron Pharma |
Humanizált programozott sejthalál 1 génnel rendelkezõ nem-humán állatok
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
KR102003754B1
(ko)
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
WO2016009017A1
(en)
|
2014-07-16 |
2016-01-21 |
Institut Gustave-Roussy |
Combination of oncolytic virus with immune checkpoint modulators
|
|
WO2016014148A1
(en)
|
2014-07-23 |
2016-01-28 |
Mayo Foundation For Medical Education And Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
US10385101B2
(en)
|
2014-08-08 |
2019-08-20 |
Vlp Therapeutics, Llc |
Virus like particle comprising modified envelope protein E3
|
|
WO2016020538A1
(en)
*
|
2014-08-08 |
2016-02-11 |
Transgene Sa |
Hbv vaccine and antibody combination therapy to treat hbv infections
|
|
CN106795513B
(zh)
|
2014-08-08 |
2021-06-11 |
Vlp治疗公司 |
包含修饰的包膜蛋白e3的病毒样颗粒
|
|
CA2957717C
(en)
*
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
CA2960102C
(en)
|
2014-09-11 |
2023-10-24 |
Vlp Therapeutics, Llc |
Flavivirus virus like particle
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
US20160101128A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
AU2015331923B2
(en)
*
|
2014-10-17 |
2020-12-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
|
|
EP3226900A4
(en)
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
WO2016121574A1
(ja)
*
|
2015-01-29 |
2016-08-04 |
コニカミノルタ株式会社 |
相互作用する分子を有する血中細胞の同時検出方法
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
EP3256156B1
(en)
|
2015-02-13 |
2025-02-12 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
|
KR20170129902A
(ko)
|
2015-03-23 |
2017-11-27 |
조운스 테라퓨틱스, 인크. |
Icos에 대한 항체
|
|
WO2016162867A1
(en)
*
|
2015-04-08 |
2016-10-13 |
Efranat Ltd. |
Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
|
|
PT3292153T
(pt)
*
|
2015-05-04 |
2019-11-05 |
Affimed Gmbh |
Combinação de um anticorpo cd30xcd16a com um anticorpo antagonístico anti-pd-1 para terapia
|
|
EP3090751A1
(en)
*
|
2015-05-06 |
2016-11-09 |
Université de Lausanne |
Molecular profiling of cd8 t-cells in autochthonous melanoma identifies maf as driver of exhaustion
|
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
MX388405B
(es)
*
|
2015-05-29 |
2025-03-19 |
Genentech Inc |
Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
|
DK3858859T3
(da)
*
|
2015-07-14 |
2025-12-15 |
Bristol Myers Squibb Co |
Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
JP2018526989A
(ja)
|
2015-08-07 |
2018-09-20 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
MY187739A
(en)
|
2015-08-11 |
2021-10-18 |
Wuxi Biologics Cayman Inc |
Novel anti-pd-1 antibodies
|
|
WO2017031760A1
(zh)
*
|
2015-08-27 |
2017-03-02 |
杨光华 |
干涉片段及其应用
|
|
WO2017031761A1
(zh)
*
|
2015-08-27 |
2017-03-02 |
杨光华 |
干涉片段及其应用
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
HK1251158A1
(zh)
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
|
CN108136010A
(zh)
*
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
SMT202200118T1
(it)
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
US10294299B2
(en)
|
2016-01-22 |
2019-05-21 |
MabQuest SA |
Immunological reagents
|
|
DK3411398T3
(da)
*
|
2016-02-05 |
2024-06-24 |
Orionis Biosciences BV |
Målrettede terapeutiske midler og anvendelse heraf
|
|
CN109069626A
(zh)
|
2016-02-12 |
2018-12-21 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
|
WO2017155981A1
(en)
|
2016-03-07 |
2017-09-14 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
|
TWI840950B
(zh)
*
|
2016-03-14 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低pd-l1表現之寡核苷酸
|
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
US11185555B2
(en)
|
2016-04-11 |
2021-11-30 |
Noah James Harrison |
Method to kill pathogenic microbes in a patient
|
|
US11649283B2
(en)
|
2016-04-15 |
2023-05-16 |
Immunext, Inc. |
Anti-human vista antibodies and use thereof
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
BR112019000015A2
(pt)
|
2016-06-30 |
2019-04-24 |
Oncorus, Inc. |
distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
|
|
NZ749997A
(en)
|
2016-07-05 |
2022-11-25 |
Beigene Ltd |
Combination of a pd-l antagonist and a raf inhibitor for treating cancer
|
|
JP2019528311A
(ja)
|
2016-08-03 |
2019-10-10 |
ネクストキュア インコーポレイテッド |
Ｌａｉｒシグナル伝達を調節するための組成物及び方法
|
|
EP3497128A2
(en)
|
2016-08-09 |
2019-06-19 |
Kymab Limited |
Anti-icos antibodies
|
|
EP3500299B1
(en)
|
2016-08-19 |
2023-12-13 |
BeiGene Switzerland GmbH |
Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
|
|
EP3504239B1
(en)
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
|
JP2019533645A
(ja)
|
2016-09-16 |
2019-11-21 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
CN106480027A
(zh)
*
|
2016-09-30 |
2017-03-08 |
重庆高圣生物医药有限责任公司 |
CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA
|
|
EP3523434A1
(en)
*
|
2016-10-07 |
2019-08-14 |
Secarna Pharmaceuticals GmbH & Co. KG |
Novel approach for treating cancer
|
|
EP3666794A1
(en)
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
US11013802B2
(en)
|
2016-12-07 |
2021-05-25 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
WO2018115051A1
(en)
|
2016-12-22 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
|
BR112019014187A2
(pt)
|
2017-01-09 |
2020-02-11 |
Tesaro, Inc. |
Métodos de tratamento de câncer com anticorpos anti-pd-1
|
|
WO2018132516A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
KR102089371B1
(ko)
*
|
2017-01-26 |
2020-03-16 |
사회복지법인 삼성생명공익재단 |
혈관면역아세포성 t 세포 림프종 진단용 마커 및 이의 용도
|
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
PL3606955T3
(pl)
|
2017-04-05 |
2025-02-24 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
|
|
KR102713203B1
(ko)
|
2017-05-30 |
2024-10-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 양성 종양의 치료
|
|
KR20240155979A
(ko)
|
2017-05-30 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
KR102757960B1
(ko)
|
2017-06-26 |
2025-01-22 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
|
CN107253988B
(zh)
*
|
2017-07-19 |
2021-01-29 |
福州大学 |
一种人源程序性死亡因子配体pd-l2蛋白的制备方法
|
|
BR112020003533A2
(pt)
|
2017-08-25 |
2020-11-17 |
Five Prime Therapeutics, Inc. |
anticorpos b7-h4 e métodos de uso dos mesmos
|
|
CN107596374B
(zh)
*
|
2017-09-01 |
2020-06-30 |
广东医科大学 |
B12蛋白表达抑制剂及其在结核病免疫和治疗中应用
|
|
US11685782B2
(en)
|
2017-10-23 |
2023-06-27 |
Children's Medical Center Corporation |
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019124441A1
(en)
|
2017-12-20 |
2019-06-27 |
Vlp Therapeutics, Llc |
Alphavirus replicon particle
|
|
JP2021506883A
(ja)
|
2017-12-21 |
2021-02-22 |
メルサナ セラピューティクス インコーポレイテッド |
ピロロベンゾジアゼピン抗体結合体
|
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
BR112020014929A2
(pt)
|
2018-01-23 |
2020-12-08 |
Nextcure, Inc. |
Composição farmacêutica, métodos para aumentar, para reduzir, para intensificar ou induzir uma resposta imune em um indivíduo, molécula, anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo, ácido nucleico, anticorpo monoclonal anti-b7h4 ou fragmento de ligação ao antígeno do mesmo, anticorpo anti-b7h4 ou fragmento de ligação ao antígeno do mesmo, cadeias leve e pesada de anticorpo anti-b7h4, e, cadeias leve e pesada de anticorpo
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
CN111741978A
(zh)
|
2018-02-21 |
2020-10-02 |
戊瑞治疗有限公司 |
B7-h4抗体制剂
|
|
EP3759142A1
(en)
|
2018-03-02 |
2021-01-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
CN108530537B
(zh)
*
|
2018-03-29 |
2019-07-02 |
中国人民解放军军事科学院军事医学研究院 |
Pd-1/pd-l1信号通路抑制剂
|
|
WO2019207942A1
(ja)
*
|
2018-04-27 |
2019-10-31 |
OTA Takayo |
免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
CN120714023A
(zh)
|
2018-06-20 |
2025-09-30 |
因赛特公司 |
抗pd-1抗体及其用途
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
WO2020043683A1
(en)
|
2018-08-27 |
2020-03-05 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
|
WO2020047345A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
|
WO2020063433A1
(zh)
*
|
2018-09-29 |
2020-04-02 |
四川科伦博泰生物医药股份有限公司 |
抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
|
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CN113195467A
(zh)
|
2018-12-11 |
2021-07-30 |
施万生物制药研发Ip有限责任公司 |
适用作alk5抑制剂的萘啶和喹啉衍生物
|
|
CN110092826B
(zh)
*
|
2019-02-28 |
2022-04-15 |
天津大学 |
CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
|
|
CN110452870A
(zh)
*
|
2019-05-20 |
2019-11-15 |
河南省肿瘤医院 |
一种肿瘤特异性t细胞的分离培养方法及由其获得的产品
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
EP4061809A1
(en)
|
2019-11-22 |
2022-09-28 |
Theravance Biopharma R&D IP, LLC |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
|
US20210154281A1
(en)
|
2019-11-26 |
2021-05-27 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
|
EP4126824A1
(en)
|
2020-03-31 |
2023-02-08 |
Theravance Biopharma R&D IP, LLC |
Substituted pyrimidines and methods of use
|
|
EP4135847A4
(en)
|
2020-04-17 |
2024-05-15 |
VLP Therapeutics, Inc. |
Coronavirus vaccine
|
|
CA3174651A1
(en)
|
2020-04-30 |
2021-11-04 |
Vlp Therapeutics, Inc. |
Cytokine immunotherapy
|
|
CA3178260A1
(en)
|
2020-05-13 |
2021-11-18 |
Massachusetts Institute Of Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
|
AU2021364837A1
(en)
|
2020-10-23 |
2023-05-25 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022165403A1
(en)
|
2021-02-01 |
2022-08-04 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
KR20240099259A
(ko)
|
2021-10-14 |
2024-06-28 |
아스널 바이오사이언시스, 인크. |
공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
|
|
EP4197525A1
(en)
|
2021-12-20 |
2023-06-21 |
Scandion Oncology A/S |
Combination of drugs for the treatment of cancer
|
|
CN114181310B
(zh)
*
|
2022-02-14 |
2022-07-05 |
中山康方生物医药有限公司 |
抗tigit抗体、其药物组合物及用途
|
|
WO2023194656A1
(en)
|
2022-04-08 |
2023-10-12 |
Tilt Biotherapeutics Oy |
Monoclonal pd-l1 antibodies
|
|
CN114588258B
(zh)
*
|
2022-05-10 |
2023-04-25 |
中山大学 |
Bmp9联合nk细胞和pd-l1抗体在制备肝癌药物方面的应用
|
|
WO2023242235A1
(en)
|
2022-06-14 |
2023-12-21 |
Scandion Oncology A/S |
Abcg2 inhibitor and nae inhibitor for the treatment of cancer
|
|
US20260053903A1
(en)
|
2022-08-19 |
2026-02-26 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
|
AU2023361162A1
(en)
|
2022-10-11 |
2025-05-29 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
|
EP4622631A1
(en)
|
2022-11-23 |
2025-10-01 |
University of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|
|
TW202511486A
(zh)
*
|
2023-07-28 |
2025-03-16 |
美商黛瑟納製藥公司 |
用於程式化死亡配體受體（ｐｄ－ｌ１）表現之組成物和方法
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|